Wechselwirkungen · Prevymis
PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-139818 · Präparat HOS-098408
12 Concomitant Effect on concentration† Recommendations concerning co- medicinal product mean ratio (90% confidence administration with letermovir interval) for AUC, Cmax (likely mechanism of action) sirolimus‡ ↑ sirolimus Frequent monitoring of sirolimus whole (2 mg single dose)/ AUC 3.40 (3.01, 3.85) blood concentrations should be performed letermovir (480 mg Cmax 2.76 (2.48, 3.06) during treatment, when changing daily) letermovir administration route, and at (CYP3A inhibition) discontinuation of letermovir and the dose of sirolimus adjusted accordingly#. Interaction not studied. Frequent monitoring of sirolimus Expected: concentrations is recommended at ↔ letermovir initiation or discontinuation of cyclosporine co-administration with letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sirolimus (HOS-085172) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 1aad03bf6d6b854585855e9c87d057abcb11e4ceb1fd58eee0f0788994f371ff · Zeichen 23776–25048 im Abschnitt